Skip to playerSkip to main content
After-the-fact Expert
Alnylam Pharmaceuticals shares plunged 25.18% as investors digested its third-quarter results and updated outlook. The RNAi drugmaker reported $1,292 million in global net product revenue, up 52% from Q3 2025, while management said full-year TTR product sales were expected at the low end of its $4.2 billion to $4.5 billion range. The company also expanded target enrollment for its TRITON-CM study and said it remained on track to achieve its 2026 financial guidance.

For informational and educational purposes only. Not financial advice.

#ALNY #BiotechStocks #MarketRecap #Earnings
Transcript
00:00Alnilam Pharmaceuticals plunged 25.18% today. What happened?
00:06Alnilam develops and sells medicines that silence genetic instructions behind harmful proteins,
00:13including treatments for ATTR amyloidosis and other rare diseases.
00:18What happened was investors focused on a weaker sales outlook, despite a headline earnings beat.
00:25The company said in a filing that quarterly earnings per share were 16.26, versus an estimate of 1.65.
00:35But Yahoo! reported that management now expects full-year TTR product sales at the low end of its existing range.
00:43That softer outlook, along with reported Medicare access concerns and pipeline delays,
00:49followed the earnings update and put pressure on the shares.
00:53Healthcare rose 2.41% today, so this move ran against its own sector.
01:00A new post-market recap every trading day.

Recommended